Anika Therapeutics Market capitalization 2024

The Anika Therapeutics Market capitalization history

YEAR	REVENUE (undefined USD)	GROSS MARGIN (%)	NET INCOME (undefined USD)
2028e	240.21	42,92	18.61
2027e	220.12	46,83	13.31
2026e	197.48	52,20	9.45
2025e	185.53	55,56	8.77
2024e	174.26	59,16	-1.61
2023	166.66	61,85	-82.67
2022	156.2	59,92	-14.9
2021	147.8	56,09	4.1
2020	130.5	52,87	-24
2019	114.6	74,96	27.2
2018	105.6	70,36	18.7
2017	113.4	75,93	31.8
2016	103.4	76,79	32.5
2015	93	77,31	30.8
2014	105.6	80,21	38.3
2013	75.1	69,64	20.6
2012	71.4	59,38	11.8
2011	64.8	58,64	8.5
2010	55.6	57,01	4.3
2009	40.1	66,08	3.7
2008	35.8	63,13	3.6
2007	30.8	61,36	6
2006	26.8	58,58	4.6
2005	29.8	62,75	5.9
2004	26.5	62,26	11.2

Anika Therapeutics Aktienanalyse

What does Anika Therapeutics do?

Anika Therapeutics Inc is a global biotechnology company specializing in the development and manufacturing of therapeutic products for orthopedic, ophthalmologic, and dermatologic treatment. It was founded in 1992 in Bedford, Massachusetts and has since maintained its headquarters there while expanding its operations worldwide. Business model Anika Therapeutics' business model is based on the development, manufacturing, and commercialization of innovative and cost-effective medical devices that use natural substances to enable rapid and powerful repair of the human body in various orthopedic, ophthalmologic, and dermatologic conditions. The company leverages its expertise in hyaluronan biology and technology to produce products based on this substance for the regeneration and healing of tissues such as cartilage, skin, and eyes. History Anika Therapeutics was founded by Charles Sherwood and Jeffrey Palmer to develop a synthetic hyaluronic acid product for the treatment of joint disorders. The first clinical study was conducted in 1996, and Anika received FDA approval for the product, marketed as Orthovisc, in 1999. Since then, Anika has expanded its presence in the industry through acquisitions, partnerships, and expansion into new geographical areas. Divisions Orthopedics In orthopedics, Anika Therapeutics offers a wide range of products for the treatment of joint disorders such as osteoarthritis and arthritis. These include Orthovisc, the company's original product, as well as Monovisc, a single-component viscosupplement that allows for easy injection into the joint, thus reducing the procedure and recovery time. Another product is Cingal, a combination product of hyaluronic acid and corticosteroid that provides effective pain relief. Ophthalmology Anika Therapeutics also manufactures products for ophthalmology. The company has a portfolio of products used for surgical procedures such as cataract surgery and vitrectomy (a surgery on the eye's vitreous body). These are available under the brand names Visian and Amvisc. Dermatology Anika Therapeutics is also active in dermatology, where it offers products for skin regeneration. This portfolio includes solutions such as Hyalofill, a hyaluronic acid-based filler substance used for restoring skin elasticity and treating wrinkles and scars. In summary, Anika Therapeutics is a global biotechnology company specializing in the development, manufacturing, and commercialization of therapeutic products in the field of orthopedics, ophthalmology, and dermatology. The company leverages its expertise in hyaluronan biology and technology to develop innovative and cost-effective medical devices that enable rapid and powerful repair of the human body in various conditions. Since its founding in 1992, the company has built a successful history of growth and expansion through acquisitions, partnerships, and expansion into new geographical areas. Anika Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Anika Therapeutics's Market Capitalization

Anika Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Anika Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Anika Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Anika Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Anika Therapeutics Stock

What is the current Anika Therapeutics market capitalization?

The current market capitalization of Anika Therapeutics is 391.02 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Anika Therapeutics.

How has the market capitalization of Anika Therapeutics developed in recent years?

The market capitalization of Anika Therapeutics has increased/decreased by -0.52% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Anika Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Anika Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Anika Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Anika Therapeutics pay?

Over the past 12 months, Anika Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anika Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Anika Therapeutics?

The current dividend yield of Anika Therapeutics is .

When does Anika Therapeutics pay dividends?

Anika Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anika Therapeutics?

Anika Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Anika Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anika Therapeutics located?

Anika Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anika Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anika Therapeutics from 6/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/4/2024.

When did Anika Therapeutics pay the last dividend?

The last dividend was paid out on 6/4/2024.

What was the dividend of Anika Therapeutics in the year 2023?

In the year 2023, Anika Therapeutics distributed 0 USD as dividends.

In which currency does Anika Therapeutics pay out the dividend?

The dividends of Anika Therapeutics are distributed in USD.